Genetic factors in type 2 diabetes: The end of the beginning?

Science

Volumn 307, Issue 5708, 2005, Pages 370-373

  O'Rahilly, Stephen ^a   Barroso, Inês ^b   Wareham, Nicholas J ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c MRC EPIDEMIOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DISEASES; HEALTH;

DIABETES; GENETIC VARIANTS; MONOGENIC FORMS;

GENETIC ENGINEERING;

GLUCOSE;

MEDICINE;

ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; LIFESTYLE; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; HUMANS; LIFE STYLE; MULTIFACTORIAL INHERITANCE; MUTATION; RISK FACTORS; VARIATION (GENETICS);

EID: 12344279952     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1104346     Document Type: Review

References (29)

1. M. I. McCarthy, P. Froguel, Am. J. Physiol. Endocrinol. Metab. 283, E217 (2002).
2. J. Tuomilehto et al., N. Engl. J. Med. 344, 1343 (2001).
3. C. N. Hales, D. J. Barker, Br. Med. Bull. 60, 5 (2001).
4. A. T. Hattersley et al., Nature Genet. 19, 268 (1998).
5. H. Beck-Nielsen, A. Vaag, P. Poulsen, M. Gaster, Best Pract. Res. Clin. Endocrinol. Metab. 17, 445 (2003).
6. A. Stride, A. T. Hattersley, Ann. Med. 34, 207 (2002).
7. S. O'Rahilly, Eur. J. Endocrinol. 147, 435 (2002).
8. D. Altshuler et al., Nature Genet. 26, 76 (2000).
9. I. Barroso et al., Nature 402, 880 (1999).
10. J. M. Friedman, Nature Med. 10, 563 (2004).
11. S. O'Rahilly, I. S. Farooqi, G. S. Yeo, B. G. Challis, Endocrinology 144, 3757 (2003).
12. D. Accili et al., Nature Genet. 12, 106 (1996).
13. Y. S. Tsai et al., J. Clin. Invest. 114, 240 (2004).
14. L. A. Sargeant, N. J. Wareham, K. T. Khaw, Int. J. Obes. Relat. Metab. Disord. 24, 1333 (2000).
15. J. P. Hugot et al., Nature 411, 599 (2001).
16. Y. Horikawa et al., Nature Genet. 26, 163 (2000); erratum in Nature Genet. 26, 502 (2000).
17. Y. Horikawa et al., Nature Genet. 26, 163 (2000); erratum in Nature Genet. 26, 502 (2000).
18. J. C. Cohen et al., Science 305, 869 (2004).
19. A. L. Gloyn et al., Diabetes 52, 568 (2003).
20. L. Love-Gregory et al., Diabetologia 46, 136 (2003).
21. I. Barroso et al., PLoS Biol. 1, 41 (2003).
22. Q. Zhu et al., Diabetologia 46, 567 (2003).
23. K. Silander et al., Diabetes 53, 1141 (2004).
24. L. D. Love-Gregory et al., Diabetes 53, 1134 (2004).
25. J. Poulton et al., Hum. Mol. Genet. 11, 1581 (2002).
26. R. A. Hegele, H. Cao, S. B. Harris, A. J. Hanley, B. Zinman, Diabetes Care 22, 524 (1999).
27. S. J. Huxtable et al., Diabetes 49, 126 (2000).
28. L. M. Hart et al., J. Clin. Endocrinol. Metab. 84, 1002 (1999).
29. We thank the Wellcome Trust (S.O'R., I.B., and N.J.W.), the Medical Research Council UK (S.O'R. and N.J.W.), and the European Union Framework Programme (S.O'R., I.B., and N.J.W.) for their continuing support. S.O'R. has a financial relationship with and is a member of the Scientific Advisory Boards of Prosidion Ltd. and Biovitrum AB. He is a member of the Scientific Advisory Boards of Cambridge Antibody Technology, Cambridge Biotechnology Ltd., Paradigm Therapeutics PLC, and Xcellsyz Ltd. He is a consultant for Merck & Co. Inc., Unilever PLC, and Ingenium Pharmaceutical AG.